drugset / Trial / NCT04740398
A Study of CBP-1008 in Patients With Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1008, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.
Timeline
- Start
- 2019-03-06
- Primary completion
- 2024-09
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBP-1008 | Other / unclassified | — | Intravenous |